TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects must have a PiZZ genotype confirmed at screening~* Plasma AAT levels indicating severe deficiency at screening~Key Exclusion Criteria:~* History of a medical condition that could negatively impact the ability to complete the study~* Solid organ, or hematological transplantation or is currently on a transplant list~* History of use of gene therapy or RNAi therapy at any time previously~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-864 in the treatment period for 28 days.
- VX-864 100 mg (Type: EXPERIMENTAL): Participants received VX-864 100 milligrams (mg) every 12 hours (q12h) in the treatment period for 28 days.
- VX-864 300 mg (Type: EXPERIMENTAL): Participants received VX-864 300 mg q12h in the treatment period for 28 days.
- VX-864 500 mg (Type: EXPERIMENTAL): Participants received VX-864 500 mg q12h in the treatment period for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written permission from parent or legal guardian~2. Age younger than 91 days~3. Likely to survive beyond the first 48 hours after enrollment~4. Sufficient intravascular access (either peripheral or central) to receive study drug.~   AND ONE OF THE FOLLOWING~5. 1) Physical, radiological, and/or bacteriological findings of a complicated intra-abdominal infection. These include peritonitis, NEC (Necrotizing Enterocolitis) Grade II or higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous perforation, meconium ileus with perforation, bowel obstruction with perforation, as evidenced by free peritoneal air on abdominal radiograph, intestinal pneumatosis or portal venous gas on abdominal radiographic examination.~OR 2) Possible NEC OR 3) Otherwise receiving meropenem per local standard of care~Exclusion criteria:~1. Renal dysfunction evidenced by urine output \<0.5 mL/hr/kg over the prior 24 hours~2. Serum creatinine \>1.7 mg/dL~3. History of clinical seizures or EEG (Electroencephalogram) confirmed seizures~4. Concomitant treatment with another carbapenem (ertapenem or imipenem) at the time of informed consent~5. Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Meropenem (Type: EXPERIMENTAL): These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA \<2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and \<91 days; Group 3: GA at birth 32 weeks or older - PNA \<2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and \<91 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Experience With Abatacept in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Male or Female subjects of more than 18 years old~* Patients with a diagnosis of established moderate to severe active RA (as per the American College of Rheumatology revised criteria, 1987), who at their physician's discretion are treated with Abatacept according to the SmPC in Europe and the Product Monograph in Canada (initiating or already on treatment for maximum 3 months) and for whom baseline characteristics are available~Exclusion Criteria:~* Patients who are currently included in any interventional clinical trial in RA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RA patients treated with Abatacept (Type: None): RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years~* Subjects who obtain a minimum sum score, considering SAR related symptoms (mean value), as defined by the protocol~Exclusion Criteria:~* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety~* Have used forbidden concomitant medications as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Common criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:~1. Had completed the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study.~2. Was capable of understanding and complying with protocol requirements.~3. Signed a written informed consent form prior to the initiation of any study procedure.~Exclusion Criteria:~Common criteria that applied to participants completing both the core phase 2/3 sulfonylurea add-on study and those completing the core phase 2/3 metformin add-on study:~1. With clinical manifestation of hepatic impairment (eg, an aspartate aminotransferase or alanine aminotransferase value of 2.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).~2. With clinical manifestation of renal impairment (eg, a creatinine value of 1.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 sulfonylurea add-on study or the core phase 2/3 metformin add-on study).~3. With serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease (eg, a subject who requires hospital admission).~Criteria that applied only to participants completing the core phase 2/3 metformin add-on study:~1. With history or symptoms of lactic acidosis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-living men and women age 65 and older~* Age-related cognitive decline as defined by (a) self-reported cognitive dysfunction that is attributed to the aging process (in response to screening questions to the participant); (b) ability to complete cognitive battery, but still scoring less than 1 standard deviation above age-matched norms at both baseline and after the two-week cognitive training lead-in.~Exclusion Criteria:~* Known dementia or other clinical neurodegenerative illness (e.g., Parkinson's disease, cerebrovascular disease) per self-report, informant report, medical records, or neuropsychological testing~* Any current psychiatric disorder~* Medical conditions that suggest shortened lifespan, such as metastatic cancer; or would prohibit safe participation in the interventions, including cardiovascular disease or musculoskeletal conditions; or with the assessments.~* Sensory impairment that would prevent participation~* IQ \< 70 as estimated by the Wechsler Test of Adult Reading~* Alcohol or substance abuse within 6 months~* Concurrent cognitive training, such as brain-training software, or other interventions expected to affect neuroplasticity~* Psychotropic medications or those with likely CNS effects (none within 4 weeks prior to study entry)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vortioxetine plus cognitive training (Type: EXPERIMENTAL): Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
- Placebo plus cognitive training (Type: PLACEBO_COMPARATOR): Placebo plus cognitive training 5 times weekly for 30 minutes a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Psychotic patients with schizophrenia who require rapid intervention~* experiencing symptoms of a psychotic disorder~* capable of choosing to be treated~Exclusion Criteria:~* Patients with a known hypersensitivity to the study drugs~* have participated in an investigational drug trial within 30 days of study initiation~* known to be unresponsive to treatment with risperidone or the comparator drug~* known to have benzodiazepine dependence (addiction to this class of anti-anxiety drugs)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* -Patients diagnosed with FD according to the ROME III criteria i) Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to obtaining informed consent ii) Have not received upper endoscopy within the last 6 months prior to enrollment and do not have evidence of structural/organic disease iii) Must have one or more of the following symptoms:~  1. Bothersome postprandial fullness~ 2. Early satiation~ 3. Epigastric pain~ 4. Epigastric burning~* At least one of the FD-related symptoms on the Global Overall Symptom (GOS) scale (bothersome postprandial fullness, early satiation, epigastric pain, epigastric burning) is ≥4, whereas heartburn is ≤3.~* Total score of depression-related symptoms on Hospital Anxiety and Depression Score (HAD) is ≤10.~* Type of visit: Outpatient~* Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study.~Exclusion Criteria:~* Confirmed ulcer (excluding scars) or malignant tumor in the upper GI~* Suspected organic lesions in the hepato-biliary-pancreatic regions such as cholelithiasis, hepatitis, pancreatitis~* History of upper GI resection~* Serious complications (liver, kidney, heart, or blood disease or metabolic disease)~* Less than a year since testing positive for H. pylori or have undergone a successful eradication therapy~* Use of prohibited medications~* Neuropsychiatric disorders~* Use of or planned use of any investigational drugs~* Unable to take drugs orally~* History of allergic reactions to Kampo medicines~* Pregnant or lactating women or those who are planning to conceive during the study period~* Deemed ineligible by principal investigator or sub-investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rikkunshito Placebo (Type: PLACEBO_COMPARATOR): None
- Rikkunshito (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anesthetic Blockades and Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic migraine~Exclusion Criteria:~* Other primary headaches~* Other secondary headaches~* Co-morbid medical diseases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Anesthetic blockades with bupivacaine (Type: EXPERIMENTAL): Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
- Isotonic saline injection (Type: PLACEBO_COMPARATOR): Patients will receive a bilateral occipital injection with isotonic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elevated LDL-C of \>3.0 mmol/L and \<5.7 mmol/L~* Fasting triglyceride concentration ≤2.8 mmol/L~* Body weight \>60.0 kg; body mass index (BMI) between 19.00 kg/m2 and \<35.00 kg/m2~* Adequate blood counts, liver and renal function~* May not received any lipid lowering drug/agent within the 30 days prior to the screening~* Non-smokers for at least 3 months~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control~* Males agree to use appropriate contraception~* Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent~Exclusion Criteria:~* Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection~* Multiple drug allergies or know sensitivity to oligonucleotide~* History of drug abuse and/or alcohol abuse~* Receiving an investigational agent within 3 months prior to study drug administration~* Subjects with safety laboratory test results deemed clinical significant by the Investigator;~* Received prescription drugs within 4 weeks of first dosing~* Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration;~* Received megadose vitamin therapy or dietary supplements within 4 weeks prior to screening~* Subjects who have used prescription drugs within 4 weeks of first dosing~* Considered unfit for the study by the Principal Investigator~* Employee or family member of the sponsor or the clinical study site personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ALN-PCS02 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed classical Hodgkin's lymphoma~  * No lymphocyte-predominant histology~ * Stage II, III, or IV disease~ * Newly diagnosed disease~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Creatinine \< 2.0 mg/dL~* Bilirubin \< 5 mg/dL~* Not pregnant or nursing~* No HIV positivity~* Hepatitis B surface antigen negative~* No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for Hodgkin's lymphoma~* Steroids allowed if medically required before chemotherapy initiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- R-ABVD (Type: EXPERIMENTAL): ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m\^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m\^2 Cycles 2, 4, and 6 Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a documented diagnosis of COPD defined according to the guidelines of the American Thoracic Society (ATS) / European Respiratory Society (ERS);~* smokers or former smokers with a smoking history of at least 10 pack / years;~* subjects with a post-bronchodilator forced expiratory volume at the 1st second (FEV1)/ forced vital capacity (FVC) ratio of \< 0.7 and a FEV1 \<50% pred;~* subjects with a high impact of the COPD on their health status (CAT≥10);~* clinical history of at least 1 moderate exacerbation / year;~* COPD patients being treated with BDP/FF NEXThaler® 100/6 μg in extra-fine formulation no more than 1 (one) week before enrollment.~Exclusion Criteria:~* an exacerbation in the four weeks prior to enrollment;~* other coexisting lung diseases (bronchial asthma, restrictive diseases or bronchiectasis) and severe co-morbidities associated with COPD, such as uncontrolled cardiovascular disease, pneumonia or cancer;~* pregnant patients;~* subjects unable to meet the criteria of acceptability and repeatability of pulmonary function tests, according to the ATS / ERS document

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 43 COPD (Type: None): COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of a written informed consent~* Men or women who are 30 to 80 years of age~* Female patients: postmenopausal or surgically sterile~* Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL~* Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents~Exclusion Criteria:~* Type 1 diabetes~* New York Heart Association heart failure Class III or IV~* Treatment with chronic insulin~* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists.~* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)~* Creatinine levels above 1.2 mg/dL~* Received any investigational product in other clinical studies within 30 days~* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete